Dirucotide
Also known as: AAB‑001, Dirucotide, MBP 82-98, MBP8298, MBP83‑99
Source Dirucotide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Dirucotide (AAB‑001) is a synthetic 17‑mer peptide derived from human myelin basic protein (residues 83‑99). It has been evaluated in Phase II/III clinical trials as an immunotherapy for relapsing‑remitting multiple sclerosis but has not received regulatory approval.
Mechanism of Action
induces antigen-specific immune tolerance to myelin basic protein, modulating autoreactive T‑cell responses in multiple sclerosis
Routes of Administration
Goals & Uses
- Reduction of relapse rate in MSNeurological / AutoimmuneLow
- Slow progression of secondary progressive multiple sclerosisNeurological / AutoimmuneLow
- Multiple SclerosisAutoimmune DiseaseModerate
- Induction of antigen-specific immune toleranceImmunomodulationModerate
Contraindications
- Hypersensitivity to Dirucotide or excipientsAllergyModerate
- Known hypersensitivity to dirucotide or any excipientAllergy / HypersensitivityHigh
- Active systemic infectionInfectiousModerate
Adverse Effects
- Hypersensitivity reactionsImmunologicRare
- Flu-like symptomsSystemic/ImmunologicalUncommon
- Flu‑like symptomsSystemicUncommon
- Injection site painLocalCommonPain at the injection site
- Injection site / infusion reactionsLocal/SystemicUncommon
Drug Interactions
- Immunosuppressants (e.g., corticosteroids)Moderate
- Immunosuppressants (e.g., corticosteroids, mitoxantrone)Moderate
Population Constraints
- Pediatric patientsAgeRelative
- Pregnant or breastfeeding womenReproductiveRelative
- Pregnant womenReproductiveRelative
- Patients with severe immunodeficiencyImmune StatusRelative
Regulatory Status
- European UnionUnapprovedNo marketing authorization; clinical trials conducted under EU Clinical Trial Regulation.
- United StatesInvestigationalIND holder Asterias Biotherapeutics; no FDA approval.
- United KingdomUnapprovedNot licensed by MHRA; used only in research settings.
Investigational New Drug (IND) status in the US; no marketing authorization in EU or UK.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Dirucotide?
Dirucotide (AAB‑001) is a synthetic 17‑mer peptide derived from human myelin basic protein (residues 83‑99). It has been evaluated in Phase II/III clinical trials as an immunotherapy for relapsing‑remitting multiple sclerosis but has not received regulatory approval.
What is Dirucotide used for?
Dirucotide is educationally associated with: Reduction of relapse rate in MS, Slow progression of secondary progressive multiple sclerosis, Multiple Sclerosis, Induction of antigen-specific immune tolerance. Educational only — not medical advice.
How is Dirucotide administered?
Recorded routes of administration: Intradermal, Intravenous, Subcutaneous.
What are the potential side effects of Dirucotide?
Reported adverse effects include: Hypersensitivity reactions, Flu-like symptoms, Flu‑like symptoms, Injection site pain, Injection site / infusion reactions. This list is not exhaustive — consult a qualified clinician.
Who should avoid Dirucotide?
Recorded contraindications: Hypersensitivity to Dirucotide or excipients, Known hypersensitivity to dirucotide or any excipient, Active systemic infection. Consult a qualified clinician before use.